Evidence map›Paper›PMID 31506425›Full record

ArticleCell death & disease2019

High throughput circRNA sequencing analysis reveals novel insights into the mechanism of nitidine chloride against hepatocellular carcinoma.

Dan-Dan Xiong, Zhen-Bo Feng, Ze-Feng Lai, Yue Qin, Li-Min Liu, Hao-Xuan Fu, Rong-Quan He, Hua-Yu Wu, Yi-Wu Dang, Gang Chen and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 76 citations in OpenAlex.

  1. Article
  2. SMARCD1 and Its Functional Relevance in SWI/SNF and Cancer.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Role of cell cycle-related geneWorld journal of clinical oncology · 2025
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Anchoring super-enhancer-driven oncogenic lncRNAs for anti-tumor therapy in hepatocellular carcinoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Dan-Dan XiongDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Zhen-Bo FengDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Ze-Feng LaiPharmaceutical College, Guangxi Medical University, Nanning, China.
Yue QinPharmaceutical College, Guangxi Medical University, Nanning, China.
Li-Min LiuDepartment of Toxicology, Pharmaceutical College, Guangxi Medical University, Nanning, China.
Hao-Xuan FuPharmaceutical College, Guangxi Medical University, Nanning, China.
Rong-Quan HeDepartment of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Hua-Yu WuDepartment of Cell Biology & Genetics, School of Preclinical Medicine, Guangxi Medical University, Nanning, China.
Yi-Wu DangDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China. dangyiwu@126.com.
Gang ChenDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China. chengang@gxmu.edu.cn.ORCID http://orcid.org/0000-0002-4864-1451
Dian-Zhong LuoDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Guangxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nitidine chloride (NC) has been demonstrated to have an anticancer effect in hepatocellular carcinoma (HCC). However, the mechanism of action of NC against HCC remains largely unclear. In this study, three pairs of NC-treated and NC-untreated HCC xenograft tumour tissues were collected for circRNA sequencing analysis. In total, 297 circRNAs were differently expressed between the two groups, with 188 upregulated and 109 downregulated, among which hsa_circ_0088364 and hsa_circ_0090049 were validated by real-time quantitative polymerase chain reaction. The in vitro experiments showed that the two circRNAs inhibited the malignant biological behaviour of HCC, suggesting that they may play important roles in the development of HCC. To elucidate whether the two circRNAs function as "miRNA sponges" in HCC, we identified circRNA-miRNA and miRNA-mRNA interactions by using the CircInteractome and miRwalk, respectively. Subsequently, 857 miRNA-associated differently expressed genes in HCC were selected for weighted gene co-expression network analysis. Module Eigengene turquoise with 423 genes was found to be significantly related to the survival time, pathology grade and TNM stage of HCC patients. Gene functional enrichment analysis showed that the 423 genes mainly functioned in DNA replication- and cell cycle-related biological processes and signalling cascades. Eighteen hubgenes (SMARCD1, CBX1, HCFC1, RBM12B, RCC2, NUP205, ECT2, PRIM2, RBM28, COPS7B, PRRC2A, GPR107, ANKRD52, TUBA1B, ATXN7L3, FUS, MCM8 and RACGAP1) associated with clinical outcomes of HCC patients were then identified. These findings showed that the crosstalk between hsa_circ_0088364 and hsa_circ_0090049 and their competing mRNAs may play important roles in HCC, providing interesting clues into the potential of circRNAs as therapeutic targets of NC in HCC.

Indexed as

Carcinoma, HepatocellularLiver Neoplasms, ExperimentalRNA, CircularRNA, NeoplasmRNA-SeqAnimalsBenzophenanthridinesCell Line, TumorChromobox Protein Homolog 5Gene Expression Regulation, NeoplasticHumansMiceMice, NudeXenograft Model Antitumor AssaysBenzophenanthridinesCBX1 protein, humanChromobox Protein Homolog 5nitidineRNA, CircularRNA, Neoplasm

Identifiers

PMID31506425
PMCPMC6737102
OpenAlexW2972418453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.